Revvity Q1 Revenue Jumps 7%, Beats Estimates; Divests China Immunodiagnostics Business
summarizeSummary
Revvity reported strong first-quarter results, with revenue increasing 7% year-over-year to $711.12 million, slightly exceeding analyst expectations. Adjusted EPS also beat consensus at $1.04 versus $1.02. Alongside the earnings beat, the company announced a strategic divestiture of its China Immunodiagnostics business, which represented approximately 6% of its 2025 revenue, as part of its portfolio optimization efforts. The company also provided a positive 2026 pro forma outlook, forecasting revenue of $2.81-$2.84 billion and adjusted EPS of $5.20-$5.30. This positive earnings report and strategic move are significant for Revvity, especially as the stock has been trading near its 52-week low, potentially providing a catalyst for upward movement. Traders will be watching how the market reacts to the combined news of strong performance and strategic restructuring.
At the time of this announcement, RVTY was trading at $85.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $81.22 to $118.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.